Trials / Unknown
UnknownNCT03692663
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Clinical Study on the Safety and Efficacy of Anti-PSMA CAR NK Cells in Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Allife Medical Science and Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TABP EIC | A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14. |
| BIOLOGICAL | Cyclophosphamide | Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion. |
| BIOLOGICAL | fludarabine | Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion. |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2023-06-01
- Completion
- 2024-06-01
- First posted
- 2018-10-02
- Last updated
- 2022-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03692663. Inclusion in this directory is not an endorsement.